|
Post by coo2002coo on Jan 21, 2016 9:50:58 GMT -5
We really have no idea of what capabilities or competitive advantages RLS has and why MNKD picks this firm. We also do not know who is behind RLS and what track records they have to rest MNKD assure they are the good partner.
|
|
|
Post by mindovermatter on Jan 21, 2016 9:53:34 GMT -5
Boy, this ground breaking news makes me want to...
|
|
|
Post by mindovermatter on Jan 21, 2016 9:54:07 GMT -5
We really have no idea of what capabilities or competitive advantages RLS has and why MNKD picks this firm. We also do not know who is behind RLS and what track records they have to rest MNKD assure they are the good partner. As the saying goes, Beggars can't be choosers.
|
|
|
Post by mnholdem on Jan 21, 2016 9:54:38 GMT -5
CEO Pfeffer is sticking with the plan. This announcement is listed under the bullet point that speaks to Technosphere licensing and partnership agreements to be fast-tracked, building a portfolio for future growth, "beginning with the licensing agreement about to be announced."
|
|
|
Post by bradleysbest on Jan 21, 2016 9:55:15 GMT -5
I guess no big BP wanted in on this?
|
|
|
Post by stevil on Jan 21, 2016 9:57:17 GMT -5
In short, this is a start. Gets the momentum rolling. But it's not going to sustain the company and we need much more than this in the future if we hope to stay in business. royalty is based of sales and not profitability / production costs / ? haha was this reply to me? I stated as much and nothing different. These drugs will likely not be blockbusters. One can hope if they want to, but even assuming best case scenario, this deal does little more than help us expand our portfolio and maybe buy us a couple months short term (or maybe none depending on how long it takes to get FDA approval, adoption, marketing, etc) and even then, it'll likely be years before we really get any sort of cash infusion from this deal. My point was that it's an attempt, and my fear is that it's the best we can do right now. Which means we're on a long and arduous path to profitability and we're going to have to get creative if we want to keep the lights on. We need much better than this if we're going to become a legitimate company in the next 5- 10 years.
|
|
|
Post by hawaiiguy42 on Jan 21, 2016 9:57:57 GMT -5
CEO Pfeffer is sticking with the plan. This announcement is listed under the bullet point that speaks to Technosphere licensing and partnership agreements to be fast-tracked, building a portfolio for future growth, "beginning with the licensing agreement about to be announced."
Now thats what I'm talking about, factual information.
|
|
|
Post by nuklerfizzacist on Jan 21, 2016 10:00:02 GMT -5
For the sake of the prior baseball analogies that were posted here; no it's not the homerun many here are yearning for but I'll take this sweet little single to start the rally.... P.S. Stevil...depends on what the ~10% is based off of ...right? :-) as an optimist I'm thinking it must be 5-10 percent of more than you may be thinking. ..just my guess. ;-)
|
|
|
Post by liane on Jan 21, 2016 10:00:23 GMT -5
In short, this is a start. Gets the momentum rolling. But it's not going to sustain the company and we need much more than this in the future if we hope to stay in business. That's the crux - it's a start, and we needed to start somewhere. Right now I'll take any positive news and trust that there will be more collaborations to follow.
|
|
|
Post by stevil on Jan 21, 2016 10:03:23 GMT -5
In short, this is a start. Gets the momentum rolling. But it's not going to sustain the company and we need much more than this in the future if we hope to stay in business. That's the crux - it's a start, and we needed to start somewhere. Right now I'll take any positive news and trust that there will be more collaborations to follow. I'm proud of management for doing all they can to ensure the success of the company. It's really all they can do at this point. Kudos to them for trying so hard. I just hope we can keep the lights on long enough for these kinds of partnerships to be beneficial. Otherwise, we're essentially giving the company away for free. It's hard to imagine more companies wouldn't be willing to make deals like these with the state we're currently in.
|
|
|
Post by mindovermatter on Jan 21, 2016 10:06:20 GMT -5
In short, this is a start. Gets the momentum rolling. But it's not going to sustain the company and we need much more than this in the future if we hope to stay in business. That's the crux - it's a start, and we needed to start somewhere. Right now I'll take any positive news and trust that there will be more collaborations to follow. One thing to keep in mind is that this deal seems to encompass EVERYTHING Mannkind is working on and not just one indication. While it would be nice to know who is behind Receptor, we might just be seeing the tip of a very big iceberg ( a good kind and not the kind that sunk the Titanic.)
|
|
|
Post by suebeeee1 on Jan 21, 2016 10:08:46 GMT -5
I guess no big BP wanted in on this? We've all seen what a big BP can do for MNKD. We may as well find out what a hungry new one will do.. Since, unless we decide to sell and never look back, we may as well enjoy the ride. (Or try)
|
|
|
Post by mnholdem on Jan 21, 2016 10:09:44 GMT -5
Single-digit/low double-digit royalty deals comprise the majority of biotech agreements today. MannKind would pay NONE of the development, production and eventual marketing expenses whatsoever. These deals can still be quite lucrative and there are plenty of examples in the market today.
|
|
|
Post by mindovermatter on Jan 21, 2016 10:10:32 GMT -5
For the sake of the prior baseball analogies that were posted here; no it's not the homerun many here are yearning for but I'll take this sweet little single to start the rally.... P.S. Stevil...depends on what the ~10% is based off of ...right? :-) as an optimist I'm thinking it must be 5-10 percent of more than you may be thinking. ..just my guess. ;-) right, it's slow roller up the third base line and we are seeing if Mannkind is fast enough to run to first before the third baseman can bare hand it and throw Mannkind out. TBD.
|
|
|
Post by mindovermatter on Jan 21, 2016 10:12:40 GMT -5
Single-digit/low double-digit royalty deals comprise the majority of biotech agreements today. MannKind would pay NONE of the development, production and eventual marketing expenses whatsoever. These deals can still be quite lucrative and there are plenty of examples in the market today. good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private.
|
|